Fate Therapeutics (FATE) Interest & Investment Income (2013 - 2026)

Fate Therapeutics (FATE) has 14 years of Interest & Investment Income data on file, last reported at $1.9 million in Q1 2026.

• Quarterly Interest & Investment Income fell 44.03% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.6 million (down 41.83% YoY) and the FY2025 annual result came in at $11.1 million, down 36.07% from the prior year.
• Interest & Investment Income declined to $1.9 million in Q1 2026, from $2.2 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $4.8 million in Q2 2024 to a low of $418000.0 in Q1 2022.
• A 5-year average of $3.1 million and a median of $3.3 million in 2025 frame the typical range for Interest & Investment Income.
• Annual changes were most pronounced in 2022 — Interest & Investment Income jumped 869.7% — and 2026, when it plunged 44.03%.
• Tracing FATE's Interest & Investment Income over 5 years: stood at $2.9 million in 2022, then surged by 53.26% to $4.4 million in 2023, then declined by 12.23% to $3.9 million in 2024, then slumped by 42.69% to $2.2 million in 2025, then retreated by 15.9% to $1.9 million in 2026.
• The last three Interest & Investment Income figures came in at $1.9 million (Q1 2026), $2.2 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.